Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet E Dancey

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Cancer Cell|May 18, 2004
Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrowJanet E Dancey
Expert Review of Anticancer Therapy|July 11, 2009
Kinase Inhibitor 4 Minisymposium summaryJanet E Dancey
Expert Opinion on Investigational Drugs|April 19, 2005
Inhibitors of the mammalian target of rapamycinJanet E Dancey
Cancer Biology & Therapy|September 14, 2006
Therapeutic targets: MTOR and related pathwaysJanet E Dancey
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
mTOR inhibitors in hematologic malignanciesJanet E Dancey
Drugs|May 25, 2007
Epidermal growth factor receptor inhibitors in non-small cell lung cancerJanet E Dancey
Hematology/Oncology Clinics of North America|January 7, 2003
Clinical development of mammalian target of rapamycin inhibitorsJanet E Dancey
Cancer Biology & Therapy|December 23, 2003
Recent advances of molecular targeted agents: opportunities for imagingJanet E Dancey
Future Oncology (London, England)|July 8, 2011
Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignanciesJanet E Dancey, Jose Monzon
Lancet (London, England)|July 11, 2003
Targeting epidermal growth factor receptor--are we missing the mark?Janet E Dancey, Boris Freidlin
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Cancer Cell|May 18, 2004
Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrowJanet E Dancey
Expert Review of Anticancer Therapy|July 11, 2009
Kinase Inhibitor 4 Minisymposium summaryJanet E Dancey
Expert Opinion on Investigational Drugs|April 19, 2005
Inhibitors of the mammalian target of rapamycinJanet E Dancey
Cancer Biology & Therapy|September 14, 2006
Therapeutic targets: MTOR and related pathwaysJanet E Dancey
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
mTOR inhibitors in hematologic malignanciesJanet E Dancey
Drugs|May 25, 2007
Epidermal growth factor receptor inhibitors in non-small cell lung cancerJanet E Dancey
Hematology/Oncology Clinics of North America|January 7, 2003
Clinical development of mammalian target of rapamycin inhibitorsJanet E Dancey
Cancer Biology & Therapy|December 23, 2003
Recent advances of molecular targeted agents: opportunities for imagingJanet E Dancey
Future Oncology (London, England)|July 8, 2011
Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignanciesJanet E Dancey, Jose Monzon
Lancet (London, England)|July 11, 2003
Targeting epidermal growth factor receptor--are we missing the mark?Janet E Dancey, Boris Freidlin
Pageof 5